(αS)-alpha-amino-3-[(4-carboxyphenyl)methyl]-3,4-dihydro-5-iodo-2,4-dioxo-1(2H)-pyrimidinepropanoic acid

UBP 301 is an antagonist of the kainate receptor, an ionotropic glutamate receptor (apparent K_d = 5.94 μM). It displays ~30-fold selectivity over AMPA receptors. UBP 301 is used to assess the roles of kainate receptors in neuronal signaling, particularly in reference to neuropathic pain.

UBP 301 is an antagonist of kainate receptors. UBP 301 is the N3-4-carboxybenzyl substituted analog II of Willardiine, which was found to be equipotent at AMPA and GLUK5-containing kainate receptors in the neonatal rat spinal cord.

Potent kainate receptor antagonist (apparent K d = 5.94 mM). Displays ~ 30-fold selectivity over AMPA receptors.

Store at +4°C

[1] JULIA C A MORE. Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists[J]. British Journal of Pharmacology, 2009, 138 6: 1093-1100. DOI: 10.1038/sj.bjp.0705148
[2] SUZANNE DOOLEN. Peripheral nerve injury increases glutamate-evoked calcium mobilization in adult spinal cord neurons.[J]. Molecular Pain, 2012, 8: 56. DOI: 10.1186/1744-8069-8-56
[3] DOREEN B OSGOOD. The utility of ionotropic glutamate receptor antagonists in the treatment of nociception induced by epidural glutamate infusion in rats.[J]. Surgical Neurology International, 2013, 4: 106. DOI: 10.4103/2152-7806.116791